Pfizer Inc. (PFE) stock declined during after-hour session. Let’s find out why?

Pfizer Inc. (NASDAQ: PFE) stock declined by 1.3% at the last close while the PFE stock price continued to fall by 0.05% in the after-hours session. At Pfizer, they use research and their worldwide resources to develop medications that help people live longer and better lives. In the research, development, and production of health care products, including novel medicines and vaccines, PFE seeks to set the benchmark for excellence, reliability, and value.

What is happening?

Late Friday, the Food and Drug Administration released new information on the circumstances at the former producer of Johnson & Johnson’s (JNJ) – Get Report COVID vaccine, which led to the disposal of millions of doses of the vaccine. The new information might stoke doubts about the one-shot vaccination, which was supposed to speed up the nation’s increasingly sluggish attempts to immunize Americans against the unique coronavirus.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Read More

FDA officials discovered that Emergent BioSolutions (EBS) – Get Report’s Maryland facility lacked proper waste disposal guidelines and failed to keep distinct production of the J&J shot and a similar one by AstraZeneca (AZN) – Get Report, which is not authorized for use in the United States but is widely used elsewhere.

According to the document issued by Dr. Peter Marks, head of the FDA’s Center for Biologics Evaluation and Research, cross contamination was discovered with AstraZeneca’s adenovirus-vectored vaccine that was being made in other portions of the plant.

However,

The memo follows a New York Times story that tens of millions of doses of the J&J, or Janssen, injection were unable to be utilized.

The FDA note also comes after federal health officials said that they are looking into a possible link between Pfizer (PFE) – Get Report and Moderna (MRNA) – Get Report vaccinations and rare cases of heart inflammation, or myocarditis, in younger individuals. According to a story in the Jerusalem Post, the problem was first reported in Israel in February, when a 19-year-old male was diagnosed with myocarditis less than a week after receiving his second dosage of the vaccination.

Dr. Abdulhadi Farojeh said that the fact that the symptoms appeared soon after the immunization strengthens the possibility that the inflammation was caused by an immune reaction.

In April, Military.com writer Patricia Kime uncovered that the Pentagon was documenting more than a dozen incidences of heart inflammation in military health patients who had received the Pfizer or Moderna vaccines. More recently, instances of American teenagers developing myocarditis as a result of the injections have surfaced, including one of an Oregon 15-year-old who ended up in the ER after receiving the Pfizer dose.

Related posts